The Promise of Intranasal Esketamine as a Novel and Effective Antidepressant.

[1]  Erlend S. Dørum,et al.  Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial , 2017, Translational Psychiatry.

[2]  Husseini Manji,et al.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.

[3]  M. Trivedi,et al.  A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. , 2015, The Journal of clinical psychiatry.

[4]  Ronald C Kessler,et al.  The economic burden of adults with major depressive disorder in the United States (2005 and 2010). , 2015, The Journal of clinical psychiatry.

[5]  M. Husain,et al.  Defining treatment-resistant depression: a comprehensive review of the literature. , 2014, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[6]  C. Grillon,et al.  Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression , 2012, Biological Psychiatry.

[7]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[8]  O. Andreassen,et al.  The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders , 2016, Molecular Psychiatry.

[9]  Bita Moghaddam,et al.  From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment , 2012, Neuropsychopharmacology.